Because of their role in breast cancer immunotherapy, the development of selective and efficient histone deacetylase (HDAC) inhibitors is of utmost importance for the implementation of treatment strategies based on the distinct expression patterns of HDAC isoforms. Here, HDAC9 is linked to breast carcinoma.